Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TRAIN

Financiado

Tumor Regulation Assisted by Immunity and Nanotechnology

Cancer is the number one cause of death among Europeans under 65, being estimated that half of Europeans will develop cancer at some time in their lives. Despite the significant progress made in the prevention and treatment of can... ver más

31/05/2025

I3S INSTITUTO DE...

157K€

Presupuesto del proyecto: 157K€

Líder del proyecto

I3S INSTITUTO DE INVESTIGACAO E INOVACAO EM... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-03-30

HORIZON-MSCA-2022-PF-01-01: MSCA Postdoctoral Fellowships 2022 ExpectedOutcome:

I+D

Cerrada hace 2 años

0% 100%

1 Participantes

I3S INSTITUTO DE INVESTIGAC...

156.78K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RTI2018-101309-B-C22 NANOFANTASMAS DE CELULAS EDUCADAS POR EL TUMOR COMO SISTEMAS... 218K€ Cerrado

SAF2017-89288-R TERAPIA GENICA EN GLIOBLASTOMA: UN NUEVO ABORDAJE TERAPEUTIC... 145K€ Cerrado

PID2021-126346OB-I00 DESARROLLO DE NUEVOS NANO-VEHICULOS PARA SUPERAR LA RESISTEN... 218K€ Cerrado

PID2020-117544RB-I00 NANOBOMBA TERMOFORETICA DIRIGIDA Y CELULAS CAR MONITORIZADAS... 171K€ Cerrado

PID2021-127622OB-I00 GLICOPEPTIDOS Y GLICOPROTEINAS CON APLICACIONES EN LA TERAPI... 254K€ Cerrado

PLEC2022-009217 ENCAPSULACIÓN DE CÉLULAS CART EN SISTEMAS POROSOS NANOESTRUC... 357K€ Cerrado

Duración del proyecto: 26 meses Fecha Inicio: 2023-03-30
Fecha Fin: 2025-05-31

Líder del proyecto

I3S INSTITUTO DE INVESTIGACAO E INOVACAO EM... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 157K€

Descripción del proyecto Cancer is the number one cause of death among Europeans under 65, being estimated that half of Europeans will develop cancer at some time in their lives. Despite the significant progress made in the prevention and treatment of cancer in recent years, this disease continues to claim lives and straining the European health and social systems and economies. In addition, cancer incidence and mortality are predicted to raise as consequence of the COVID-19 pandemic. To reduce these dramatic repercussions, innovative therapies, more effective and accessible to a wider population, are needed to treat patients with advanced cancer. The overarching aim of the TRAIN project is to leverage the enzyme activities in the tumor microenvironment to boost the efficacy of cancer immunotherapies via molecularly engineered peptide nanomaterials capable of metabolic modulation of tumors and release of chemotherapeutic drugs. TRAIN is focused on pancreatic adenocarcinoma (PAAD) and will develop biomimetic 3D PAAD models to test the proposed combined chemo- and immuno-therapy. The feasibility of this major goal will be achieved through a multidisciplinary approach that will employ concepts from peptide nanotechnology, enzymology, immunology and cancer biology, together with cutting-edge materials science, proteomics and cell biology methods. TRAIN is in line with The Europe’s Beating Cancer Plan, aimed at reducing the negative impact of cancer for patients, their families and healthcare systems, and addressing cancer-associated disparities across countries, while providing training and career development opportunities for a young and creative researcher at the intersection of peptide nanotechnology and cancer immunology.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores